Chinese Health: Wholly-owned subsidiary receives drug registration acceptance notice.

Health notice for Chinese people: Recently, our wholly-owned subsidiary Jiangsu Shenhua Pharmaceutical Co., Ltd. received the "Acceptance Notice" for the application for registration and market approval of fumarate Vonora tablets issued by the National Medical Products Administration. This drug is a new type of potassium ion competitive acid blocker which can reversibly inhibit the H+/K+-ATP enzyme on the gastric wall cells in a competitive manner without relying on acidic environment. It is more stable in a strong acidic environment, and can quickly, effectively, and persistently inhibit the secretion of gastric acid by the gastric wall cells, significantly reducing the occurrence of elevated nighttime gastric acid. On December 18, 2019, it was officially approved for sale in China for the treatment of gastroesophageal reflux disease, becoming the first potassium ion competitive acid blocker to enter China.